This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Aerovate Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Aerovate Therapeutics'in kazançlarının artacağı tahmin edilmektedir. EPS'nin büyümesi yıllık 19.5% oranında azalması beklenmektedir.

Anahtar bilgiler

18.7%

Kazanç büyüme oranı

19.49%

EPS büyüme oranı

Biotechs kazanç büyümesi	25.4%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	28 Mar 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Oct 01

Here's Why Aerovate Therapeutics (NASDAQ:AVTE) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Jun 11

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Summary Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The global Pulmonary Arterial Hypertension market size is expected to reach $12.2 billion by 2032. Aerovate has been able to take what was achieved with oral Imatinib and convert it to a dry inhaled powder that can be used to treat pulmonary arterial hypertension. AV-101 can become standard of care for PAH, when added to background therapy for PAH patients, if it can be shown to be superior to Merck's Winrevair. Read the full article on Seeking Alpha

Analiz Makalesi • May 24

Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • Feb 09

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Oct 17

We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Jul 04

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analiz Makalesi • Feb 28

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Aerovate Therapeutics...

Analiz Makalesi • Jan 06

A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Key Insights Aerovate Therapeutics' estimated fair value is US$27.2 based on 2 Stage Free Cash Flow to Equity Current...

Analiz Makalesi • Oct 14

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analiz Makalesi • Jul 01

Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Jan 22

We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Sep 30

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:AVTE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	N/A	-21	N/A	N/A	1
12/31/2026	N/A	-14	N/A	N/A	2
12/31/2025	N/A	-24	N/A	N/A	3
3/31/2025	N/A	-49	-50	-50	N/A
12/31/2024	N/A	-70	-71	-71	N/A
9/30/2024	N/A	-85	-75	-75	N/A
6/30/2024	N/A	-88	-75	-75	N/A
3/31/2024	N/A	-82	-69	-69	N/A
12/31/2023	N/A	-76	-57	-57	N/A
9/30/2023	N/A	-70	-57	-57	N/A
6/30/2023	N/A	-64	-51	-51	N/A
3/31/2023	N/A	-57	-45	-45	N/A
12/31/2022	N/A	-52	-39	-39	N/A
9/30/2022	N/A	-45	-38	-37	N/A
6/30/2022	N/A	-37	-34	-34	N/A
3/31/2022	N/A	-31	-29	-29	N/A
12/31/2021	N/A	-23	-28	-27	N/A
9/30/2021	N/A	-18	-17	-17	N/A
6/30/2021	N/A	-15	-13	-13	N/A
3/31/2021	N/A	-11	-10	-10	N/A
12/31/2020	N/A	-10	-8	-8	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: AVTE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: AVTE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: AVTE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: AVTE şirketinin gelirinin US pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: AVTE gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: AVTE 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/04/29 21:27
Gün Sonu Hisse Fiyatı	2025/04/28 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Aerovate Therapeutics, Inc. 2 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Vasiliana Moussatos	Wedbush Securities Inc.
Laura Chico	Wedbush Securities Inc.

This company is no longer active

Aerovate Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 24% to US$39.67

Price target increased to US$33.25

Price target increased to US$26.00

Recent updates

Aerovate Therapeutics, Inc. Declares Special Dividend, Payable on April 29, 2025

Aerovate Therapeutics Announces Range of Expected Cash Dividend

Jade Biosciences, Inc. entered into a definitive merger agreement to acquire Aerovate Therapeutics, Inc. (NasdaqGM:AVTE) in a reverse merger transaction.

Aerovate Therapeutics Provides Update on Nasdaq Audit Committee Compliance

Aerovate Therapeutics, Inc. Approves the Appointment of Habib J. Dable as Member of the Audit Committee

Aerovate Therapeutics, Inc. Announces Resignation of Maha Katabi as Board of Directors and Member of Audit Committee and Compensation Committee

Here's Why Aerovate Therapeutics (NASDAQ:AVTE) Must Use Its Cash Wisely

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2B Portion of Impahct Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Aerovate Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

CFO & Treasurer exercised options and sold US$185k worth of stock

Founder exercised options and sold US$192k worth of stock

Price target increased by 24% to US$39.67

CFO & Treasurer notifies of intention to sell stock

Aerovate Therapeutics, Inc. Announces Board Changes

Chief Medical Officer notifies of intention to sell stock

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$213k worth of stock

New major risk - Revenue and earnings growth

Chief Scientific Officer notifies of intention to sell stock

Founder notifies of intention to sell stock

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2B Portion and Enrollment of First Patient into Phase 3 in the Impahct Trial Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension

We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Founder notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Aerovate Therapeutics, Inc. Appoints Habib Dable as Member of Board of Directors

CEO & Director notifies of intention to sell stock

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director exercised options and sold US$259k worth of stock

CEO & Director exercised options and sold US$325k worth of stock

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

CEO & Director exercised options and sold US$308k worth of stock

Aerovate Therapeutics, Inc. Appoints Donald Santel To Its Board of Directors

CEO & Director exercised options and sold US$374k worth of stock

A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Price target increased to US$33.25

CEO & Director exercised options and sold US$238k worth of stock

CFO & Treasurer notifies of intention to sell stock

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

High number of new and inexperienced directors

Founder exercised options and sold US$420k worth of stock

Aerovate Therapeutics, Inc. Presents Novel Phase 2B/Phase 3 Impahct Trial Design At Chest Annual Meeting 2022

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Founder exercised options and sold US$325k worth of stock

Founder exercised options and sold US$154k worth of stock

Price target increased to US$26.00

Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell 2000 Growth Index

Aerovate Therapeutics, Inc. Announces New Executive Appointments

Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

Aerovate Therapeutics, Inc., Annual General Meeting, Jun 21, 2022

High number of new and inexperienced directors

We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

High number of new and inexperienced directors

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Aerovate Therapeutics, Inc. has completed an IPO in the amount of $121.549988 million.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi